Lessons learned from Percutaneous Indirect Annuloplasty in the Treatment of Mitral Regurgitation and Future Perspectives
Main Article Content
Abstract
Mitral annuloplasty is the most performed surgical procedure in the treatment of mitral valve regurgitation. However, the morbidity and mortality risks associated with this procedure limit its broader application, especially in patients with comorbidities or less severe mitral valve regurgitation. A less invasive percutaneous approach associated with lesser morbidity might offer advantages compared with mitral annuloplasty in some patients. In order to find such an approach, the use of the coronary sinus has been extensively explored. The anatomical relationship between the coronary sinus and the posterior annulus of the mitral valve inspired several creative solutions to restore mitral leaflets coaptation. Coronary sinus annuloplasty attempts to replicate the results of surgical annuloplasty by reducing the antero-posterior diameter of the mitral annulus. In the present manuscript, we performed a systematic review of the devices using the coronary sinus as a key element to correct mitral regurgitation, including two devices still in preclinical phase and those currently awaiting premarket approval. We discussed the most recently published results related to percutaneous annuloplasty, highlighted the pros and cons of each approach, and summarized the lessons learned to improve clinical results.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Newell P, Tartarini R, Hirji S, et al. Observed versus expected morbidity and mortality in patients undergoing mitral valve repair. Interact Cardiovasc Thorac Surg. 2022;35(5):ivac24.
3. Tomšič A, Hiemstra YL, van Hout FMA, et al. Long-term results of mitral valve repair for severe mitral regurgitation in asymptomatic patients. J Cardiol. 2018;72(6):473-479.
4. Newell P, Tartarini R, Hirji S, et al. Observed versus expected morbidity and mortality in patients undergoing mitral valve repair. Interact Cardiovasc Thorac Surg. 2022;35(5):ivac241.
5. Watkins, AR, Fialka, N, EL-Andari, R, et al. Mortality and morbidity of surgical and transcatheter mitral valve repair in octogenarians: A systematic review. J Card Surg. 2022;37:2752- 2760.
6. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358-1365.
7. Tuladhar SM, Punjabi PP. Surgical reconstruction of the mitral valve. Heart. 2006;92(10):1373-7.
8. Orban M, Lüsebrink E, Braun D, et al. Recent advances in patient selection and devices for transcatheter edge-to-edge mitral valve repair in heart failure. Expert Rev Med Devices. 2020;17(2):93-102.
9. De Bonis M, Lapenna E, Maisano F, et al. Long-term results (≤18 years) of the edge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation: implications for the percutaneous approach. Circulation. 2014;130(11 Suppl 1):S19-24.
10. Kaye DM , Byrne M., Alferness C, et al. Feasibility and short-term efficacy of percutaneous mitral annular reduction for therapy of heart failure-induced mitral regurgitation. Circulation. 2003; 108:1795-1797
11. Barker CM, Lindenfeld J. Indirect Annuloplasty for Functional Mitral Regurgitation. JACC Heart Fail. 2019;7(11):956-957.
12. Maselli D, Guarracino F, Chiaramonti F, Mangia F, Borelli G, Minzioni G. Percutaneous mitral annuloplasty: an anatomic study of human coronary sinus and its relation with mitral valve annulus and coronary arteries. Circulation. 2006;114(5):377-80
13. Choure AJ, Garcia MJ, Hesse B, et al. In vivo analysis of the anatomical relationship of coronary sinus to mitral annulus and left circumflex coronary artery using cardiac multidetector computed tomography: implications for percutaneous coronary sinus mitral annuloplasty. J Am Coll Cardiol. 2006;48:1938–45.
14. Rottländer D, Gödde M, Degen H, Ögütcü A, Saal M, Haude M. Procedural planning of CS-based indirect mitral annuloplasty using CT-angiography. Catheter Cardiovasc Interv. 2021;98(7):1393-1401.
15. Chahine J, Baranowski B, Tarakji K, et al. Cardiac venous injuries: procedural profiles and outcomes during left ventricular lead placement for cardiac resynchronization therapy. Heart Rhythm. 2020;17:1298–1303.
16. Harnek J, Webb JG, Kuck KH, et al. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation). JACC Cardiovasc Interv. 2011;4:115-122.
17. Sack S, Kahlert P, Bilodeau L, et al. Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv. 2009;2(4):277-84
18. Machaalany J, St-Pierre A, Sénéchal M, et al. Fatal late migration of viacor percutaneous transvenous mitral annuloplasty device resulting in distal coronary venous perforation. Can J Cardiol. 2013;29(1):130.e1-4.
19. Sack S, Kahlert P, Erbel R. Percutaenous mitral valve: A non-stented coronary sinus device for the treatment of functional mitral regurgitation in heart failure patients. Minim Invasive Ther Allied Technol. 2009;18(3):156-63
20. Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. 2009;120(4):326-33.
21. Siminiak T, Wu JC, Haude M, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012;14:931–8.
22. Lipiecki J, Siminiak T, Sievert H, et al. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. Open Heart. 2016;3(2):e000411.
23. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg Sl. The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. JACC Heart Fail. 2019;7:945–5.
24. Krishnaswamy A, Kapadia SR. Indirect Mitral Annuloplasty Using the Carillon Device. Front Cardiovasc Med. 2020;7:576058.
25. Rogers, J.H., Rahdert, D.A., Caputo, G.R., et al. Long-term safety and durability of percutaneous septal sinus shortening (The PS3 System™) in an ovine model. Cathet. Cardiovasc. Intervent. 2009,;73:540-548.
26. Rogers JH, Thomas M, Morice MC, et al. Treatment of Heart Failure With Associated Functional Mitral Regurgitation Using the ARTO System: Initial Results of the First-in-Human MAVERIC Trial (Mitral Valve Repair Clinical Trial). JACC Cardiovasc Interv. 2015;8(8):1095-1104.
27. Patterson T, Gregson J, Erglis A, et al. Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation. Eur J Heart Fail. 2021;23(10):1775-1783.
28. Tozzi P, Locca D, Siniscalchi G, Aittigrine S. Percutaneous reduction of septal-to-lateral distance to increase mitral leaflet coaptation length: Preclinical study results. JTCVS Techniques. Published online November 02, 2022. doi: 10.1016/j.xjtc.2022.10.010